Edgewise Therapeutics (EWTX) said Thursday that the US Food and Drug Administration's warning to Han Phan at Rare Disease Research is "unrelated" to any of the company's clinical trials or data.
The warning letter issued on Nov. 27 following a site inspection was related to Phan's work with another company, according to Edgewise.
Edgewise said it has audited Phan's site multiple times and believes the data related to its clinical trials complies with the FDA's requirements.
Shares of the company were down 1.6% in recent trading.
Price: 31.56, Change: -0.50, Percent Change: -1.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.